

Isolation and structure determination of new chymotrypsin inhibitory peptides streptopeptolins B and C

メタデータ	言語: eng 出版者: 公開日: 2020-01-07 キーワード (Ja): キーワード (En): 作成者: Tiwari, Ankit, Kaweewan, Issara, Miyake, Yuto, Hemmi, Hikaru, Kodani, Shinya メールアドレス: 所属:
URL	http://hdl.handle.net/10297/00027004

1 **RESEARCH ARTICLE**

2

3 **Isolation and structure determination of new chymotrypsin inhibitory peptides**
4 **streptopectolins B and C**

5

6 Ankit Tiwari^a, Issara Kaweewan^b, Yuto Miyake^a, Hikaru Hemmi^c, and Shinya

7 Kodani^{a, b, d, *}

8

9 *^aGraduate School of Integrated Science and Technology, Shizuoka University, 836*

10 *Ohya, Suruga-ku, Shizuoka 422-8529, Japan;*^b*Graduate School of Science and*

11 *Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan;*

12 *^cFood Research Institute, National Agriculture and Food Research Organization*

13 *(NARO), 2-1-12 Kannondai, Tsukuba, Ibaraki 305-8642, Japan;*^d*Academic Institute,*

14 *Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan*

15

16 *To whom correspondence should be addressed: Shinya Kodani, Academic Institute,

17 Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 422-8529, Japan, Tel/Fax;

18 +81(54)238-5008, E-mail; kodani.shinya@shizuoka.ac.jp

19

20

21 **Abstract**

22 New chymotrypsin inhibitory peptides named streptopectolins B and C were
23 isolated from *Streptomyces olivochromogenes*. Structures of streptopectolins B
24 and C were determined to be cyclic depsipeptides possessing 3-amino-6-
25 hydroxy-2-piperidone unit by interpretation of NMR spectra and ESI-MS.
26 Streptopectolins B and C showed inhibitory activities to chymotrypsin with IC₅₀
27 of 8.0 and 12.0 µg/mL, respectively.

28

29 Keywords: streptopectolin, peptide, *Streptomyces olivochromogenes*,
30 chymotrypsin inhibitor

31

32 **1. Introduction**

33 Cyanopeptolin-type peptides are cyclic depsipeptides commonly possessing 3-
34 amino-6-hydroxy-2-piperidone (Ahp) unit and *N*-methylated amino acid in the
35 molecules. Cyanopeptolin-type peptides have been isolated mostly as protease
36 inhibitors from a wide variety of cyanobacteria with different names: cyanopeptolins
37 (Martin et al. 1993; Bister et al. 2004; von Elert et al. 2005), micropeptins (Okino et al.
38 1993; Ploutno et al. 2002; Yamaki et al. 2005; Kisugi and Okino 2009; Zafrir and
39 Carmeli 2010), microcystilide (Tsukamoto et al. 1993), aeruginopeptins (Harada et al.
40 2001), nostopeptins (Okino et al. 1997), nostocyclin (Kaya et al. 1996), oscillapeptins
41 (Shin et al. 1995; Sano and Kaya 1996; Itou et al. 1999), jizanpeptins (Gallegos et al.
42 2018) and somamides (Nogle et al. 2001). Cyanopeptolin-type peptides have been
43 isolated from other bacteria besides cyanobacteria. A cyanopeptolin-type peptide
44 crocapeptin was isolated from the myxobacterium *Chondromyces crocatus* Cm c5 and
45 indicated to be biosynthesized by NRPS (Viehrig et al. 2013; Zaburannyi et al. 2016).
46 Recently a cyanopeptolin-type peptide streptopeptolin (**1** in Fig. 1) was isolated from
47 *Streptomyces olivochromogenes* NBRC 3561 (Kodani et al. 2018). In addition, the
48 biosynthetic gene cluster encoding a NRPS for streptopeptolin was deduced from
49 whole genome data of *S. olivochromogenes* NBRC 3561 (Dohra et al. 2017). In this
50 report, further chemical investigation was performed on the extract of *S.*
51 *olivochromogenes*, which resulted in isolation of new two analogous peptides
52 streptopeptolins B and C (**2** and **3** in Fig. 1). Here, we describe isolation and structure
53 determination of **2** and **3** from *S. olivochromogenes*.

54 **2. Results and discussion**

55 The new peptide streptopeptolins B (**2**) and C (**3**) were purified from the extract of
56 culture of *Streptomyces olivochromogenes* NBRC 3561. The molecular formula of **2**

57 was established to be $C_{49}H_{67}N_9O_{14}$ by accurate ESI-MS analysis, as the ion
58 corresponding to $[M - H_2O]^+$ was observed at m/z 988.4790 (the calculated m/z value,
59 988.4780). To obtain the chemical structure, the NMR spectra of **2** including 1H , ^{13}C ,
60 DEPT-135, DQF-COSY, TOCSY, ROESY, HMBC, and HSQC were measured using
61 the mix solvent system (0.5 mL, MeCN- d_3 /DMSO- d_6 ; 4:1). By interpretation of
62 TOCSY and DQF-COSY spectra, proton spin systems of seven units of amino acids
63 (Gln1, Thr2, Gln3, Ahp4, Phe5, *N*-Me-Tyr6, and Ala7) were assigned as shown in Fig.
64 S3 and Table S1. The chemical shifts of **2** were very similar to those of previously
65 reported streptopectolin (Kodani et al. 2018). The assignment of Ahp unit was
66 performed mainly by TOCSY and HMBC spectra (Fig. S3). The proton spin system
67 from amide proton to δ -proton (bold line in Fig. S3) in Ahp unit was constructed by
68 TOCSY and DQF-COSY spectra. The cyclic structure in Ahp unit was constructed
69 by HMBC correlations from α -proton (δH 3.72) and δ -proton (δH 5.14) to carbonyl
70 carbon (δC 170.5). HMBC correlations from α -protons and amide protons to
71 carbonyl carbon in adjacent amino acids (arrow in Fig. S3) indicated the two amino
72 acid sequences (Gln1-Thr2-Gln3-Ahp4-Phe5 and *N*-Me-Tyr6-Ala7). HMBC
73 correlations (H- δ of Ahp4/C- α of Phe5, H- α of Phe5/C- δ of Ahp4, and H- α of
74 Phe5/C=O of Ahp4) indicated the structure of Ahp connecting with tertiary amide of
75 Phe. The connection between Phe and *N*-Me-Tyr was established by HMBC
76 correlations from protons of *N*-Me (δH 2.74) to carbonyl carbon (δC 170.1) of Phe.
77 The connection between Thr2 and Ala7 with lactone structure was indicated by
78 HMBC correlation from β -proton (δH 5.36) in Thr to carbonyl carbon (δC 174.8) in
79 Ala. The presence of 2-methylbut-2-enoic acid (Mba) was indicated by TOCSY
80 correlation between H-3 (δH 6.41) and H-4 (δH 1.72) and HMBC correlations from
81 H-2-Me (δH 1.79) to C-2 (δC 132.7), C-3 (δC 131.6), and carbonyl carbon (δC 170.1).

82 The connection between Gln1 and Mba was established by HMBC correlation from
83 amide proton (δH 7.50) in Gln1 to carbonyl carbon (δC 170.1) in Mba. The
84 configuration of the double bond in Mba was assigned to be *E* considering the
85 similarity of chemical shifts to tiglic acid, in the same manner with streptopeptolin
86 (Kodani et al. 2018). The proton spin system of 1-amino-2-propanol (Apn) was
87 established by TOCSY spectrum. The characteristic chemical shifts at position 2 (δH
88 3.66, δC 67.0) indicated the presence of hydroxyl residue. HMBC correlation from
89 amide proton (δH 7.16) of Apn to γ -carbonyl carbon (δC 173.5) of Gln3 indicated that
90 Apn attached to Gln3.

91 The molecular formula of **3** was established to be $\text{C}_{53}\text{H}_{74}\text{N}_{10}\text{O}_{14}$ by accurate ESI-
92 MS analysis, as the ion corresponding to $[\text{M} - \text{H}_2\text{O}]^+$ was observed at m/z 1057.5369
93 (the calculated m/z value, 1057.5358). To obtain the chemical structure, the NMR
94 spectra of **3** including ^1H , ^{13}C , DEPT-135, DQF-COSY, TOCSY, NOESY, ROESY,
95 HMBC, and HSQC were measured using the mix solvent system (0.5 mL, MeCN-
96 d_3 /DMSO- d_6 ; 4:1). The structure determination of **3** was performed by NMR analysis
97 in the same manner with **2** (Table S1 and Fig. S3). The structure of **3** was confirmed
98 to be a depsipeptide which had the same amino acid sequence with **2** (Fig. 1). In the
99 structure of **3**, *N*-(5-aminopentyl)acetamide (Apa) was attached to Gln3 instead of 1-
100 amino-2-propanol (Apn) in **2**. Briefly, TOCSY and DQF-COSY spectra indicated
101 sequential proton spin system of five sequential methylenes flanked by two amino
102 residues. HMBC correlation from methyl protons (δH 1.78) and amide proton (δH
103 7.22) to carbonyl carbon (δC 170.5) indicated the presence of acetyl residue. HMBC
104 correlation from amide proton (δH 7.18) to carbonyl carbon (δC 172.8) indicated the
105 attachment of Apa at Gln3.

106 The modified Marfey's analysis (Harada et al., 1996) was performed to determine
107 the absolute stereochemistries of Gln, Thr, Ala, Phe, and *N*-Me-Tyr in **2** and **3**. The
108 hydrolysate of **2** or **3** was analysed by HPLC after derivatization with *N*- α -(5-fluoro-2,
109 4-dinitrophenyl)-L-leucinamide (L-FDLA), to compare with standard amino acid
110 derivatives. For stereochemistry of 1-amino-2-propanol, (*R*)-1-amino-2-propanol and
111 (*S*)-1-amino-2-propanol were respectively derivatized with *N*- α -(5-fluoro-2, 4-
112 dinitrophenyl)-L-leucinamide (L-FDLA) for HPLC comparative analysis. As a result,
113 the stereochemistries of Gln, Thr, Ala, Phe and *N*-Me-Tyr in **2** and **3** were determined
114 to be L and the stereochemistry of Ahp was determined to be R. Regarding the
115 relative stereochemistry of Ahp, stereochemistry of Ahp in **2** was determined to be 3*S*,
116 6*R* or 3*R*, 6*S* by ROESY correlations (Fig. S4). The same correlation pattern was
117 observed in ROESY spectrum of **3**, which indicated that Ahp units in **2** and **3** had the
118 same relative stereochemistry. Considering biosynthesis of streptopectolin by NRPS
119 (Kodani et al. 2018), the stereochemistry of Ahp in **2** and **3** was proposed to be 3*S*, 6*R*
120 as same as that of streptopectolin.

121 Since the related peptide streptopectolin was reported to have inhibitory activity
122 against chymotrypsin (Kodani et al. 2018), the inhibitory activities of **2** and **3** was
123 tested against trypsin and chymotrypsin. As a result, compounds **2** and **3** showed
124 inhibitory activities against chymotrypsin with IC₅₀ of 8.0 and 12.0 μ g/mL,
125 respectively. However, both compounds did not inhibit trypsin at the concentration of
126 50 μ g/mL. Previously, we reported that compound **1** showed inhibitory activity
127 against chymotrypsin with IC₅₀ of 5.0 μ g/mL (Kodani et al. 2018). The compounds **2**
128 and **3** showed similar/slightly less inhibitory activities compared with **1**. Considering
129 discrepancy of the structures of **1-3** (Fig.1), modification of Gln3 did not have a
130 noticeable effect on the inhibitory activity against chymotrypsin.

131 In previous report (Kodani et al. 2018), streptopectolin was proposed to be
132 biosynthesized via NRPS (Accession number: GAX58086). In this paper, we isolated
133 two new analogous peptides that had additional modification on Gln3. We proposed
134 that the compounds **2** and **3** were also biosynthesized by same NRPS. Modification
135 residues including 1-amino-2-propanol and *N*-(5-aminopentyl)acetamide may be
136 biosynthesized from Thr and Lys through decarboxylation for both residues and
137 acetylation for *N*-(5-aminopentyl)acetamide. We found Lys/Orn decarboxylase coding
138 gene (Accession number: GAX58093) and N-acetyltransferase coding gene
139 (Accession number: GAX58092) possibly responsible for biosynthesizing *N*-(5-
140 aminopentyl)acetamide. After biosynthesizing (*R*)-1-amino-2-propanol and *N*-(5-
141 aminopentyl)acetamide, some transferase may function to attach these residues to
142 Gln3 of **1** to afford **2** and **3**. As far as our search on the region close to the
143 biosynthetic gene cluster of streptopectolin, there is no possible transferase-like
144 protein-coding gene. The biosynthetic system to afford **2** and **3** from **1** is not clear for
145 now.

146

147 **3. Experimental**

148 **3.1. Bacterial strain**

149 *Streptomyces olivochromogenes* NBRC 3561 was obtained from the NBRC culture
150 collection (Biological Resource Center, National Institute of Technology and
151 Evaluation, Chiba, Japan).

152 **3.2. Isolation of streptopectolins B and C**

153 *S. olivochromogenes* NBRC 3561 was cultured on ISP2 agar medium (2 L) at 30
154 °C for 5 days. Spores and aerial hyphae were harvested by a steel spatula after the
155 cultivation. Double volume of methanol was added to the harvested cell for extraction,

156 followed by filtration using filter paper (Whatman No.1, GE Healthcare Life Sciences,
157 Little Chalfont, UK). The filtrate was evaporated by a rotary evaporator and the
158 concentrated extract was subjected to open column chromatography (styrene-
159 divinylbenzene resin, CHP-20P, Mitsubishi Chemical Corp., Tokyo, Japan) and eluted
160 with 10% MeOH, 60% MeOH and 100% MeOH. The 100% MeOH fraction was
161 concentrated using a rotary evaporator, subjected to HPLC separation using an ODS
162 column (4.6 × 250 mm, Wakopak Handy ODS, WAKO) and an UV detector set at
163 220 nm, and eluted by 22% MeCN containing 0.05% TFA at flow rate 1 mL /min to
164 yield **2** (4.5 mg) and **3** (3.6 mg).

165 **3.3. NMR experiments**

166 NMR sample was prepared by dissolving **2** or **3** in 500 µl of mix solvent (MeCN-
167 d_3 /DMSO- d_6 , 4:1). 1D ^1H , ^{13}C , DEPT-135, and all 2D NMR spectra were obtained on
168 Bruker Avance800 spectrometer with quadrature detection following the previous
169 report (Kodani et al. 2018).

170 **3.4. MS experiments**

171 ESI-MS analyses were performed using a JEOL JMS-T100LP mass spectrometer.
172 For accurate MS analysis, reserpine was used as an internal standard.

173 **3.5. Modified Marfey's method**

174 The modified Marfey's method was applied to **2** or **3**, following previous report
175 (Kodani et al. 2018). The reagents including $N\alpha$ -(5-fluoro-2,4-dinitrophenyl)-L-
176 leucinamide (L-FDLA, Tokyo Chemical Industry Co., LTD, Tokyo, Japan) and $N\alpha$ -
177 (5-fluoro-2,4-dinitrophenyl)-D-leucinamide (D-FDLA, Tokyo Chemical Industry Co.,
178 LTD, Tokyo, Japan) were used for derivatization. The standard amino acids including
179 L-Glu, L-Thr, L-allo-Thr, L-Ala, L-Phe, and N -Me-L-Tyr were purchased from Wako
180 chemical. The HPLC analysis was performed for L-FDLA or D-FDLA derivative of L-

181 Glu, L-Thr, L-allo-Thr, and L-Ala at a flow rate of 1 mL/min using solvent A (distilled
182 water containing 0.05% TFA) and solvent B (MeCN containing 0.05% TFA) with an
183 isocratic mode from 0 to 30 min at 35 % of solvent B and a linear gradient mode from
184 30 min to 70 min increasing percentage of solvent B from 35 % to 60%. The retention
185 times (min) of L- or D-FDLA derivatized amino acids in this HPLC condition were
186 following; L-Thr-L-FDLA (13.52 min), L-allo-Thr-L-FDLA (14.29 min), L-Glu-L-
187 FDLA (20.15 min), L-allo-Thr-D-FDLA (20.42 min), L-Glu-D-FDLA (23.81 min), L-
188 Thr-D-FDLA (27.48 min), L-Ala-L-FDLA (28.36 min), L-Ala-D-FDLA (39.48 min).
189 The HPLC analysis was performed for L-FDLA or D-FDLA derivative of L-Phe, and
190 *N*-Me-L-Tyr at a flow rate of 1 mL/min using solvent A (distilled water containing
191 0.05% TFA) and solvent B (MeCN containing 0.05% TFA) with a linear gradient
192 mode from 0 min to 70 min increasing percentage of solvent B from 25 % to 60%.
193 The retention times (min) of L- or D-FDLA derivatized amino acids in this HPLC
194 condition were following; L-Phe-L-FDLA (48.74 min), L-Phe-D-FDLA (59.09 min),
195 *N*-Me-L-Tyr-L-FDLA (68.68 min), *N*-Me-L-Tyr -D-FDLA (70.98 min).

196 ***3.6. Enzyme inhibitory assay***

197 The inhibition assays using trypsin and chymotrypsin were carried out following
198 previous report (Kodani et al. 2018).

199

200 **Supplementary material**

201 The underlying research materials for this article can be accessed on line.

202

203 **Acknowledgments**

204 The NMR spectra were recorded on Bruker Avance 600 and Avance III HD 800
205 spectrometers at the Advanced Analysis Center, NARO.

206

207 **Disclosure statement**

208 No potential conflict of interest was reported by the authors.

209

210 **Funding**

211 This study was supported by the Japan Society for the Promotion of Science by
212 Grants-in-aids (grant number 16K01913).

213

214 **References**

- 215 Bister B, Keller S, Baumann HI, Nicholson G, Weist S, Jung G, Sussmuth RD, Juttner
216 F. 2004. Cyanopeptolin 963A, a chymotrypsin inhibitor of *Microcystis* PCC 7806.
217 J Nat Prod. 67:1755-1757.
- 218 Dohra H, Miyake Y, Kodani S. 2017. Draft genome sequence of *Streptomyces*
219 *olivochromogenes* NBRC 3561, a bioactive peptide-producing actinobacterium.
220 Genome Announc. 5:e01048-01017.
- 221 Gallegos DA, Sauri J, Cohen RD, Wan X, Videau P, Vallota-Eastman AO, Shaala LA,
222 Youssef DTA, Williamson RT, Martin GE et al. 2018. Jizanpeptins,
223 cyanobacterial protease inhibitors from a *Symploca* sp. cyanobacterium collected
224 in the Red Sea. J Nat Prod. 81:1417-1425.
- 225 Harada KI, Mayumi T, Shimada T, Fujii K, Kondo F, Park HD, Watanabe MF. 2001.
226 Co-production of microcystins and aeruginopeptins by natural cyanobacterial
227 bloom. Environ Toxicol. 16:298-305.
- 228 Itou Y, Ishida K, Shin HJ, Murakami M. 1999. Oscillapeptins A to F, serine protease
229 inhibitors from the three strains of *Oscillatoria agardhii*. Tetrahedron. 55:6871-
230 6882.

231 Kaya K, Sano T, Beattie KA, Codd GA. 1996. Nostocyclin, a novel 3-amino-6-
232 hydroxy-2-piperidone-containing cyclic depsipeptide from the cyanobacterium
233 *Nostoc* sp. *Tetrahedron Lett.* 37:6725-6728.

234 Kisugi T, Okino T. 2009. Micropeptins from the freshwater cyanobacterium
235 *Microcystis aeruginosa* (NIES-100). *J Nat Prod.* 72:777-781.

236 Kodani S, Komaki H, Hemmi H, Miyake Y, Kaweewan I, Dohra H. 2018.
237 Streptopectolin, a cyanopeptolin-type peptide from *Streptomyces*
238 *olivochromogenes*. *ACS Omega.* 3:8104-8110.

239 Martin C, Oberer L, Ino T, Konig WA, Busch M, Weckesser J. 1993. Cyanopeptolins,
240 new depsipeptides from the cyanobacterium *Microcystis* sp. PCC 7806. *J Antibiot*
241 (Tokyo). 46:1550-1556.

242 Nogle LM, Williamson RT, Gerwick WH. 2001. Somamides A and B, two new
243 depsipeptide analogues of dolastatin 13 from a Fijian cyanobacterial assemblage
244 of *Lyngbya majuscula* and *Schizothrix* species. *J Nat Prod.* 64:716-719.

245 Okino T, Murakami M, Haraguchi R, Munekata H, Matsuda H, Yamaguchi K. 1993.
246 Micropeptins A and B, plasmin and trypsin inhibitors from the blue-green alga
247 *Microcystis aeruginosa*. *Tetrahedron Lett.* 34:8131-8134.

248 Okino T, Qi S, Matsuda H, Murakami M, Yamaguchi K. 1997. Nostopeptins A and B,
249 Elastase Inhibitors from the Cyanobacterium *Nostoc minutum*. *J Nat Prod.*
250 60:158-161.

251 Ploutno A, Shoshan M, Carmeli S. 2002. Three novel protease inhibitors from a
252 natural bloom of the cyanobacterium *Microcystis aeruginosa*. *J Nat Prod.* 65:973-
253 978.

254 Sano T, Kaya K. 1996. Oscillapeptin G, a tyrosinase inhibitor from toxic *Oscillatoria*
255 *agardhii*. *J Nat Prod.* 59:90-92.

256 Shin HJ, Murakami M, Matsuda H, Ishida K, Yamaguchi K. 1995. Oscillapeptin, an
257 elastase and chymotrypsin inhibitor from the cyanobacterium *Oscillatoria*
258 *agardhii* (NIES-204). Tetrahedron Lett. 36:5235-5238.

259 Tsukamoto S, Painuly P, Young KA, Yang X, Shimizu Y, Cornell L. 1993.
260 Microcystilide A: a novel cell-differentiation-promoting depsipeptide from
261 *Microcystis aeruginosa* NO-15-1840. J Am Chem Soc. 115:11046-11047.

262 Viehrig K, Surup F, Harmrolfs K, Jansen R, Kunze B, Muller R. 2013. Concerted
263 action of P450 plus helper protein to form the amino-hydroxy-piperidone moiety
264 of the potent protease inhibitor crocapeptin. J Am Chem Soc. 135:16885-16894.

265 von Elert E, Oberer L, Merkel P, Huhn T, Blom JF. 2005. Cyanopeptolin 954, a
266 chlorine-containing chymotrypsin inhibitor of *Microcystis aeruginosa* NIVA Cya
267 43. J Nat Prod. 68:1324-1327.

268 Yamaki H, Sitachitta N, Sano T, Kaya K. 2005. Two new chymotrypsin inhibitors
269 isolated from the Cyanobacterium *Microcystis aeruginosa* NIES-88. J Nat Prod.
270 68:14-18.

271 Zaburannyi N, Bunk B, Maier J, Overmann J, Muller R. 2016. Genome analysis of the
272 fruiting body-forming myxobacterium *Chondromyces crocatus* reveals high
273 potential for natural product biosynthesis. Appl Environ Microbiol. 82:1945-1957.

274 Zafirir E, Carmeli S. 2010. Micropeptins from an Israeli fishpond water bloom of the
275 cyanobacterium *Microcystis* sp. J Nat Prod. 73:352-358.

276

277

278

279 Figure legends

280 Fig. 1. Chemical structures of streptopeptolins A (**1**), B (**2**) and C (**3**)

281

282 Fig. 1

